Cancer drug improves survival in patients with metastatic melanoma

Results of a University of Arizona Cancer Center’s scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic melanoma. The findings of the Phase III study of nab-paclitaxel, brand name Abraxane®, therapy compared to standard dacarbazine therapy were presented at the Society for Melanoma Research in California. Read more here.